Introduction
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). Specifically, it consists of amino acids 176 to 191 of hGH with a tyrosine residue added at the N-terminus. It was originally developed by Monash University researchers investigating whether the fat-metabolizing properties of growth hormone could be isolated from its anabolic and diabetogenic effects. This guide reviews the research conducted on AOD-9604.
Development Background
The hypothesis behind AOD-9604 was that the lipolytic (fat-breaking) activity of human growth hormone resides in a specific region of the molecule rather than being a whole-molecule effect. By isolating and testing the fragment corresponding to amino acids 176-191, researchers aimed to create a compound that could promote fat metabolism without the insulin resistance, glucose intolerance, and other side effects associated with full-length growth hormone administration.
Mechanism of Action
Research suggests AOD-9604 stimulates lipolysis (breakdown of stored fat) and inhibits lipogenesis (fat storage) through mechanisms that appear independent of the IGF-1 pathway — the primary anabolic signaling axis of full hGH. This selectivity has been a key point of interest in the research literature, as it suggests AOD-9604 may engage with fat cell metabolism through alternative receptor pathways including possible beta-3 adrenergic receptor involvement.
Animal Study Findings
Preclinical studies in obese animal models demonstrated reductions in body fat, particularly visceral fat, following AOD-9604 administration. Studies also investigated AOD-9604’s effects on cartilage and bone repair in animal models, findings that expanded research interest beyond its original lipolytic application. Some animal studies observed potential regenerative effects in cartilage tissue models.
Human Clinical Research
AOD-9604 progressed to human clinical trials focused on obesity treatment. Phase 2 trials showed a favorable safety profile with no significant effects on blood glucose, insulin levels, or IGF-1 — supporting the original hypothesis of selectivity for fat metabolism over anabolic effects. Efficacy results for weight loss were less definitive, and the compound did not progress to Phase 3 trials for obesity.
Current Research Status
AOD-9604 received Generally Recognized as Safe (GRAS) status from the FDA in 2014 as a food ingredient. Research interest continues particularly in the areas of cartilage repair and metabolic function. It is widely available as a research peptide and continues to be studied in preclinical models.
Conclusion
AOD-9604 represents an interesting research approach to isolating specific functional activities of growth hormone. Its research history demonstrates favorable metabolic selectivity and a well-characterized safety profile in human trials, while ongoing preclinical research continues to explore its potential applications beyond fat metabolism.